← ACADIA PHARMACEUTICALS INC
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||||
| Net Income (Loss) Attributable to Parent | ($271.4m) | ($289.4m) | ($245.2m) | ($235.3m) | ($281.6m) | ($167.9m) | ($216.0m) | ($61.3m) | $226.5m | $391.0m | |
| Net Income (Loss) Available to Common Stockholders, Basic | ($271.4m) | ($289.4m) | ($245.2m) | ($235.3m) | ($281.6m) | ($167.9m) | ($216.0m) | ($61.3m) | $226.5m | $391.0m | |
| Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | — | — | ($245.2m) | ($235.3m) | ($281.6m) | ($167.9m) | ($216.0m) | ($61.3m) | $226.5m | $391.0m | |
| Depreciation | $843k | $1.2m | $1.5m | $1.3m | $1.5m | $2.2m | $2.0m | $1.5m | $920k | $871k | |
| Amortization of Intangible Assets | $985k | $1.5m | $1.5m | $1.5m | $1.5m | $1.1m | $0 | $4.1m | $15.0m | $10.9m | |
| Deferred Income Tax Expense (Benefit) | — | — | — | — | — | — | — | $10.2m | $31.6m | ($250.3m) | |
| Share-based Payment Arrangement, Noncash Expense | $55.3m | $75.5m | $81.6m | $82.3m | $84.4m | $63.6m | $68.2m | $66.4m | $67.0m | $52.1m | |
| Share-based Payment Arrangement, Expense | $55.3m | $75.5m | $81.6m | $82.3m | $84.4m | $63.6m | $68.2m | $66.4m | $67.0m | $52.1m | |
| Impairment of Intangible Assets, Finite-lived | — | — | — | — | — | — | — | $0 | $0 | $0 | |
| Share-based Payment Arrangement, Expensed and Capitalized, Amount | — | — | — | — | — | $600k | $300k | $3.6m | — | — | |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property | ($5k) | ($4k) | ($88k) | ($3k) | ($281k) | $0 | $0 | — | — | — | |
| Gain (Loss) on Disposition of Intangible Assets | — | — | — | — | — | — | — | — | $146.5m | $0 | |
| Gain (Loss) on Disposition of Other Assets | — | — | — | — | — | — | — | — | $146.5m | $0 | |
| Income (Loss) from Equity Method Investments | — | — | — | — | — | ($167.5m) | ($213.4m) | ($51.0m) | $258.1m | $138.9m | |
| Income Tax Expense (Benefit) | $1.3m | $1.1m | $1.3m | $876k | $611k | $351k | $2.5m | $10.2m | $31.6m | ($252.1m) | |
| Other Nonoperating Income (Expense) | — | — | — | $997k | ($997k) | ($2.3m) | $3.5m | $5.1m | $1.8m | $2.4m | |
| Changes in operating assets and liabilities: | |||||||||||
| Additional Financial Items | |||||||||||
| Increase (Decrease) in Accounts Receivable | $5.9m | $11.4m | $8.7m | $9.7m | $12.5m | $16.1m | ($2.2m) | $36.1m | $472k | $22.7m | |
| Increase (Decrease) in Inventories | $3.3m | $1.0m | ($1.9m) | $1.7m | $3.3m | $4.2m | ($2.4m) | $28.8m | $49.5m | $18.2m | |
| Increase (Decrease) in Accounts Payable | $2.2m | $4.9m | ($5.6m) | $4.1m | $1.3m | ($1.6m) | $5.9m | $4.8m | ($1.4m) | ($5.3m) | |
| Proceeds from Stock Options Exercised | $18.0m | $26.7m | $4.4m | $96.0m | $73.8m | $13k | $3.7m | $20.3m | — | — | |
| Gain (Loss) on Investments | — | — | ($1.8m) | $997k | ($997k) | $2.3m | $3.5m | $5.1m | $0 | $0 | |
| Inventory Write-down | — | $700k | $2.7m | $1.1m | $400k | $1.3m | $600k | $900k | $500k | $2.3m | |
| Proceeds from Contributed Capital | $14.3m | — | — | — | — | — | — | — | — | — | |
| Net Cash Provided by (Used in) Operating Activities | ($208.4m) | ($217.8m) | ($167.5m) | ($151.1m) | ($136.2m) | ($125.7m) | ($114.0m) | $16.7m | $157.7m | $109.8m | |
| Cash flows from investing activities: | |||||||||||
| Payments to Acquire Property, Plant, and Equipment | $1.5m | $812k | $2.1m | $1.1m | $7.6m | $1.1m | $0 | $50k | $523k | $4.7m | |
| Net Cash Provided by (Used in) Investing Activities | ($261.9m) | $92.5m | ($71.5m) | ($165.8m) | $192.5m | ($71.1m) | $73.2m | $32.0m | ($30.5m) | ($302.6m) | |
| Cash flows from financing activities: | |||||||||||
| Proceeds from Issuance of Common Stock | $518.9m | $31.2m | $306.6m | $371.8m | $81.0m | $18.2m | $8.2m | $25.1m | $6.8m | $49.9m | |
| Net Cash Provided by (Used in) Financing Activities | $533.8m | $31.2m | $306.6m | $371.8m | $81.0m | $18.2m | $8.2m | $25.1m | $6.8m | $49.9m | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | $63.5m | ($94.1m) | $67.7m | $54.9m | $137.3m | ($178.6m) | ($32.6m) | $73.8m | $133.9m | ($142.8m) | |
| Supplemental disclosure of cash flow information: | |||||||||||
| Income Taxes Paid, Net | $365k | $1.4m | ($1.3m) | $1.6m | $1.1m | $1.0m | $2.2m | $5.8m | $19.5m | $25.2m |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.